These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. A comparison of the in vitro and in vivo thrombogenic activity of factor IX concentrates using stasis (Wessler) and non-stasis rabbit models. Prowse CV, Williams AE. Thromb Haemost; 1980 Oct 31; 44(2):81-6. PubMed ID: 6779401 [Abstract] [Full Text] [Related]
4. A novel rat model of thrombogenicity: its use in evaluation of prothrombin complex concentrates and high purity factor IX concentrates. McLaughlin LF, Drummond O, MacGregor IR. Thromb Haemost; 1992 Nov 10; 68(5):511-5. PubMed ID: 1455396 [Abstract] [Full Text] [Related]
8. Coagulation Factor IX concentrate: method of preparation and assessment of potential in vivo thrombogenicity in animal models. Menache D, Behre HE, Orthner CL, Nunez H, Anderson HD, Triantaphyllopoulos DC, Kosow DP. Blood; 1984 Dec 10; 64(6):1220-7. PubMed ID: 6498336 [Abstract] [Full Text] [Related]
9. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate. Ruiz-Sáez A, Hong A, Arguello A, Echenagucia M, Boadas A, Fabbrizzi F, Minichilli F, Bosch NB. Haemophilia; 2005 Nov 10; 11(6):583-8. PubMed ID: 16236107 [Abstract] [Full Text] [Related]
11. Cutaneous and systemic effects of varying doses of brown recluse spider venom in a rabbit model. McGlasson DL, Harroff HH, Sutton J, Dick E, Elston DM. Clin Lab Sci; 2007 Nov 10; 20(2):99-105. PubMed ID: 17557708 [Abstract] [Full Text] [Related]
13. [Thrombogenicity of a new prothrombin complex concentrate]. Klöcking HP, Klessen C, Jablonowski C, Meerbach W, Dornheim G. Folia Haematol Int Mag Klin Morphol Blutforsch; 1984 Nov 10; 111(5):645-61. PubMed ID: 6083940 [Abstract] [Full Text] [Related]
14. Toxicity of factor IX concentrates in mice. Magner A, Aronson D. Dev Biol Stand; 1979 Nov 10; 44():185-8. PubMed ID: 544292 [Abstract] [Full Text] [Related]
15. Thrombogenicity of factor IX complex: in vivo investigation. Aronson DL, Menache D. Dev Biol Stand; 1987 Nov 10; 67():149-55. PubMed ID: 3609475 [Abstract] [Full Text] [Related]
16. Impact of infusion speed on the safety and effectiveness of prothrombin complex concentrate: a prospective clinical trial of emergency anticoagulation reversal. Pabinger I, Tiede A, Kalina U, Knaub S, Germann R, Ostermann H, Beriplex P/N Anticoagulation Reversal Study Group. Ann Hematol; 2010 Mar 10; 89(3):309-16. PubMed ID: 19787352 [Abstract] [Full Text] [Related]
17. The inhibitor of prothrombin conversion in plasma of patients on oral anticoagulant treatment. Bertina RM, Westhoek-Kuipers ME, Alderkamp GH. Thromb Haemost; 1981 Jun 30; 45(3):237-41. PubMed ID: 7281102 [Abstract] [Full Text] [Related]
18. Assessment of thrombogenicity of prothrombin complex concentrates in a porcine model. Harrison J, Abildgaard C, Lazerson J, Culbertson R, Anderson G. Thromb Res; 1985 Apr 15; 38(2):173-88. PubMed ID: 4002204 [Abstract] [Full Text] [Related]
19. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity. Gray E, Tubbs J, Thomas S, Oates A, Boisclair M, Kemball-Cook G, Barrowcliffe TW. Thromb Haemost; 1995 Apr 15; 73(4):675-9. PubMed ID: 7495077 [Abstract] [Full Text] [Related]